Is CELC a Buy? What to Consider in 2026
Short answer
The bull case for CELC (CELC) rests on Gedatolisib FDA decision and launch: The July 17, 2026 PDUFA date for the HR+/HER2-/PIK3CA wild-type indication is the single largest catalyst. Revenue (TTM) is ~$0 (pre-revenue, clinical-stage). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. Whether CELC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Celcuity Inc. is a Minneapolis-based clinical-stage biotechnology company focused on targeted therapies for solid tumors. Its lead candidate, gedatolisib, is a pan-PI3K/AKT/mTOR (PAM) inhibitor being developed for HR+/HER2- advanced breast cancer. Unlike single-node inhibitors such as alpelisib, capivasertib, and everolimus, gedatolisib is designed to block the whole pathway at once. In 2026 the pivotal Phase 3 VIKTORIA-1 trial hit its primary endpoint, with gedatolisib combination regimens roughly doubling progression-free survival versus alpelisib plus fulvestrant in the PIK3CA-mutant cohort, results presented at ASCO. The FDA granted Priority Review to the New Drug Application for the PIK3CA wild-type population with a PDUFA goal date of July 17, 2026. The investment picture is the classic late-stage biotech setup: a large addressable market and strong trial data on one side, and pre-revenue economics with concentrated single-asset risk on the other. Celcuity has essentially no product revenue and funds heavy research spending from cash and a debt facility, so the stock trades on the probability and size of a gedatolisib launch rather than on trailing financials. The near-term FDA decision, the readout of additional cohorts and the VIKTORIA-2 first-line studies, and the company's ability to fund a commercial launch are the variables that matter most. Walnut is not an investment adviser, and a name like this carries outcomes that can swing sharply on single regulatory or clinical events.
What's the case for buying CELC?
1. Gedatolisib FDA decision and launch
The July 17, 2026 PDUFA date for the HR+/HER2-/PIK3CA wild-type indication is the single largest catalyst. An approval would convert Celcuity from a pre-revenue developer into a commercial-stage company, while the wider PIK3CA-mutant opportunity from VIKTORIA-1 could follow via a supplemental filing. Execution on manufacturing, pricing, and salesforce build-out then becomes the next test.
2. Differentiated pan-pathway mechanism
Gedatolisib blocks all four class I PI3K isoforms plus mTORC1 and mTORC2, aiming to close the adaptive-resistance loops that single-target drugs can leave open. In VIKTORIA-1 the combinations improved median progression-free survival by roughly 5.5 to 5.7 months versus alpelisib plus fulvestrant. If that profile holds in real-world use, it supports a premium position within the PAM-inhibitor class.
3. Label-expansion pipeline
Beyond the initial indication, the Phase 3 VIKTORIA-2 program is studying gedatolisib in first-line advanced breast cancer, including endocrine-sensitive and endocrine-resistant patients. Additional cohorts and combination regimens broaden the potential eligible population over time. Each readout is a discrete catalyst that can move the shares independent of the base indication.
What are the risks to CELC?
Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. It posted a net loss of roughly $52.8 million in the first quarter of 2026 and funds operations from cash plus a debt facility, so additional equity or debt financing (and potential dilution) is a live risk if a launch takes longer or costs more than planned. Even with approval, commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of clinical-stage biotech rather than a defect specific to this name.
How is CELC valued? (as of JUNE 2026)
Snapshot for CELC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$0 (pre-revenue, clinical-stage)
- Market cap: ~$5B
- Share price (Jun 30, 2026): ~$105
- Q1 2026 net loss: ~$52.8M
- Q1 2026 R&D expense: ~$33.1M
- Cash & short-term investments: ~$205.7M
Because Celcuity has essentially no product sales, standard multiples like price-to-earnings or price-to-sales do not apply, and the market cap reflects the expected value of a gedatolisib approval and launch. Management has said current cash plus debt-facility drawdowns are expected to fund clinical activities through 2026, which places the funding runway alongside the launch timeline as a key watch item. Figures are approximate and as of the periods noted.
How do you decide if CELC is a buy?
Rather than asking whether CELC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CELC indirectly through an index or sector ETF before adding more.
For the full picture, see the CELC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CELC against your real portfolio and see your actual exposure before deciding.
The bottom line on CELC
The bottom line: CELC's story right now is Gedatolisib FDA decision and launch, with revenue (ttm) at ~$0 (pre-revenue, clinical-stage). If you believe that narrative continues, the call is about sizing CELC sensibly and checking overlap with what you own; if you doubt it (the risk: celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CELC with Walnut
Use CELC as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CELC a good stock to buy right now?
+
The case for CELC right now is Gedatolisib FDA decision and launch, with revenue (ttm) at ~$0 (pre-revenue, clinical-stage). If you believe that thesis holds, CELC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does CELC do?
+
Celcuity Inc.
What are the main risks of CELC?
+
Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. It posted a net loss of roughly $52.8 million in the first quarter of 2026 and funds operations from cash plus a debt facility, so additional equity or debt financing (and potential dilution) is a live risk if a launch takes longer or costs more than planned. Even with approval, commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of clinical-stage biotech rather than a defect specific to this name.
What does Celcuity do?
+
Celcuity is a clinical-stage biotechnology company developing targeted cancer therapies. Its lead drug, gedatolisib, is a pan-PI3K/AKT/mTOR inhibitor being developed for HR+/HER2- advanced breast cancer, and the company also runs diagnostic and functional-testing work supporting its programs.
Does Celcuity make any money yet?
+
No. Celcuity is pre-revenue and reported a net loss of roughly $52.8 million in the first quarter of 2026. It funds heavy research spending from cash, short-term investments, and a debt facility rather than from product sales.
What is gedatolisib?
+
Gedatolisib is Celcuity's lead drug candidate, an intravenously administered inhibitor that blocks all four class I PI3K isoforms plus mTORC1 and mTORC2. The design aims to suppress the whole pathway at once and reduce the adaptive resistance that single-target drugs can trigger.
What is the FDA PDUFA date for gedatolisib?
+
The FDA granted Priority Review to the New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer and set a PDUFA goal date of July 17, 2026. That decision is the company's largest near-term catalyst.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CELC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.